Scinovex
articleTop 1% cited

Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) after a Single Intravitreal Administration

Investigative Ophthalmology & Visual Science · 2005 · Vol. 46(2) · pp. 726–726

Abstract

This study demonstrates that ranibizumab has a PK profile that is favorable for its clinical use in treating neovascular AMD by monthly ITV injection.

Retinal Diseases and TreatmentsAngiogenesis and VEGF in CancerComplement system in diseasesRanibizumabPharmacokineticsMedicineIntravitreal administrationBioavailabilityMacular degenerationClearanceOphthalmologyPharmacologyChoroidal neovascularization

MeSH terms

RanibizumabAnimalsAntibodies, MonoclonalAqueous HumorBiological AvailabilityDrug Evaluation, PreclinicalFemaleHalf-LifeImmunoglobulin Fab FragmentsInjectionsMacaca fascicularisMaleRecombinant Fusion ProteinsRetinaVitreous Body
Citations
502
FWCI
28.17
field-weighted impact
References
35
Percentile
100%
vs. same field & year
Citations per year
Related articles
Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) after a Single Intravitreal Administration
Investigative Ophthalmology & Visual Science · 2005 · 502 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.